Trials / Completed
CompletedNCT00460564
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
A Multicenter Study to Evaluate the Efficacy and Safety in Patients With Post-Stroke Upper Limb Spasticity Receiving a Double-Blind, Placebo-Controlled GSK1358820 Treatment Followed by an Open-Label GSK1358820 Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS) wrist score.
Detailed description
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS) wrist score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1358820 | botulinum toxin type A |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-04-16
- Last updated
- 2017-05-30
- Results posted
- 2010-02-10
Locations
18 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00460564. Inclusion in this directory is not an endorsement.